Name: Clarity Pharmaceuticals (CU6) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

CU6

Pharmaceuticals, Biotechnology & Life Sciences

Clarity Pharmaceuticals

Short interest: 9.75%; +1.65 pp 30d; as of 9 Oct 2026
Reported shorts: 36.4M
Shares on issue: 373.081M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Clarity Pharmaceuticals

Clarity Pharmaceuticals is a clinical-stage company specializing in radiopharmaceuticals, focusing on theranostic products that combine therapy and imaging. Utilizing its proprietary SAR Technology, Clarity aims to improve cancer treatment outcomes with its Targeted Copper Theranostic platform. The company is positioned as a leader in next-generation radiopharmaceuticals, offering products that provide high accuracy and precision in cancer treatment.

Company profile →

Clarity Pharmaceuticals (ASX:CU6) has 9.75% of its shares on issue reported as short positions as of 9 Oct 2026, or about 36,368,024 shares. Over the past 30 days that figure has risen 1.65 percentage points, and over 90 days it has risen 2.14 percentage points. Its highest recorded short interest was 10.24% in July 2025. CU6 is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads CU6 today

Zanger BreakoutWatchScore 8rank 1669 of 1893
CAN SLIMWatchScore 8rank 1250 of 1549
Minervini Trend TemplateWatchScore 8rank 1391 of 1684
Crowded-Short BreakoutSetupScore 43rank 30 of 1448
Quality compoundersWatchScore 8rank 1401 of 1660

Prices to 15 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

CU6 fundamentals

In the year to 30 Jun 2026, Clarity Pharmaceuticals (ASX:CU6) recorded revenue of A$0 and a net loss after tax of A$107.2M. A year earlier it recorded revenue of A$0 and a net loss after tax of A$64.3M. Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →